title: Multiple reaction monitoring (MRM) of plasma proteins in cardiovascular proteomics.
abstract: Different methodologies have been used through years to discover new potential biomarkers related with cardiovascular risk. The conventional proteomic strategy involves a discovery phase that requires the use of mass spectrometry (MS) and a validation phase, usually on an alternative platform such as immunoassays that can be further implemented in clinical practice. This approach is suitable for a single biomarker, but when large panels of biomarkers must be validated, the process becomes inefficient and costly. Therefore, it is essential to find an alternative methodology to perform the biomarker discovery, validation, and -quantification. The skills provided by quantitative MS turn it into an extremely attractive alternative to antibody-based technologies. Although it has been traditionally used for quantification of small molecules in clinical chemistry, MRM is now emerging as an alternative to traditional immunoassays for candidate protein biomarker validation.
authors.affiliation: Proteomics Unit, SESCAM, Hospital Nacional de Paraplejicos, Toledo, Spain.
authors.forename: Verónica M
authors.initials: VM
authors.lastname: Dardé
authors.forename: Maria G
authors.initials: MG
authors.lastname: Barderas
authors.forename: Fernando
authors.initials: F
authors.lastname: Vivanco
mesh_terms: D000478:Alkylation; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000737:chemistry / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood*; D006801:Humans; D011489:Protein Denaturation; D059748:Proteolysis; D040901:Proteomics / Q000379:methods*; D014357:Trypsin / Q000378:metabolism
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D014357:Trypsin